Tuesday, February 27th 2024 - 05:36

Final Program

Thursday May 31, 2007

8:30 - Welcome and registration

8:55 - Introduction
Pr Sylvie van der Werf, Institut Pasteur, Paris, France

Session 1 - Political and economic issues of Avian Influenza

9:00 - Avian Influenza and Human health: Focus on the situation one year after the worldwide outbreak
Dr Keiji Fukuda, Global Influenza Program, WHO, Geneva, Switzerland

9:30 - Economic impact of the avian influenza propagation
Mr Milan Brahmbhatt, Lead adviser in the east Asia region of the world bank, USA

10:00 - Avian influenza epizootie: The global situation; prevention and control strategies
Dr Bernard Vallat, OIE, Paris, France

10:30 - Break and poster session / Visit exhibition space

11:00 - Human-to-Human contamination: An increase in the cases number?
Pr Angus Nicoll, European Centre for Disease Prevention and Control, Stockholm, Sweden

11:30 - Estimation of potential global pandemic influenza mortality
Dr Christopher Murray, Harvard University, Cambridge, USA

12:00 - Discussion and remarks

12:15 - Poster session

12:40 - Lunch

Session 2 - Latest scientific advances on the H5N1 virus

14:00 - Functional genomics approaches reveal surprising mysteries of Influenza: What can the 1918 pandemic teach us about a possible H5 Avian Influenza outbreak?
Pr Michael G. Katze, University of Washington, Washington, USA

14:20 - Haemagglutinin mutations and binding of H5N1 to human-types receptors: one more step to the pandemic?
Pr Albert Osterhaus, National Influenza Centre and Department of Virology Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands

14:40 - Role of host cytokines responses in the pathogenesis of avian H5N1 influenza viruses in mice
Dr Terrence Tumpey, Centers for disease control and prevention, Atlanta, USA

15:00 - Can the structure of H5N1 neuraminidase lead to the design of new drugs?
Dr Rupert Russell, Centre for Biomolecular Sciences, St Andrews, United Kingdom

15:20 - Discussion

15:30 - Break and poster session

Session 3 - Latest scientific advances on H5N1 detection

16:00 - Diagnostic assay for H5N1 influenza viruses
Dr Nader Pourmand, Stanford University, Palo Alto, USA

16:20 - Effects of rapid real-time diagnostics on the spread of viral epidemics
Dr Jochen Kumm, Stanford University, Palo Alto, USA

16:30 - Short oral communications for sessions 1, 2 and 3

  • 16:30 Performance evaluation of five detection tests for Avian Influenza antigen with various Avian samples – Study results
    Dr Sze-Wee Tan, Rockeby Biomed Ltd, Singapore
  • 16:40 Nuclear and nucleolar targeting of influenza A virus NS1 protein: Striking differences between different virus subtypes
    Pr Ilkka Julkunen, Department of Viral Diseases and Immunology National Public Health Institute (KTL), Helsinki, Finland
  • 16:50 Sialic acid receptor binding of Influenza haemagglutinin proteins
    Dr Holly Shelton, School of Biological Sciences, University of Reading, United Kingdom

17:00 - Discussion and remarks

Gala Dinner

Friday June 1st, 2007

Session 4 - Prevention and treatments: Focus on vaccine and drugs development

9:00 - Overview on influenza vaccines and their clinical studies
Dr Martin Friede, Initiative for Vaccine Research, WHO, Geneva, Switzerland

9:30 - Pandemic influenza preparation: cross-reactive immunity with an adjuvanted H5N1 candidate vaccine
Dr Isabel Leroux-Roels, Center of Vaccinology, Ghent University and Hospital GlaxoSmithKline Biological, Ghent, Belgium

9:45 - Preclinical testing of adjuvanted-H5N1 candidate vaccines
Dr Catherine Caillet, Sanofi Pasteur, Marcy l’Etoile, France

10:00 - Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells
Dr Stacey Schultz-Cherry, Department of Medical Microbiology and Immunology University of Wisconsin, Madison, USA

10:30 - Break and poster session / Visit exhibition space

11:00 - Oseltamivir therapy in ferrets inoculated with H5N1 influenza viruses
Dr Elena Govorkova, St. Jude Children's Research Hospital,Memphis, USA

11:20 - Last advances on Oseltamivir (Tamiflu): a medical and political point of view
Dr David Reddy, Influenza Task Force, F. Hoffmann-La Roche Ltd, Basel, Switzerland

11:40 - Short oral communications

  • 11:40 Influenza virus inhibitor against wild type and mutant neuraminidase
    Dr Jovan Pavlovic, Institute of Medical Virology, University of Zurich, Switzerland
  • 11:50 Synergistic inhibition of Avian (H5N1) highly pathogenic influenza virus by POLY I:POLY C12U combined with Oseltamivir or Zanamivir
    Dr D. Strayer, Hemispherx Biopharma, Inc., Philadelphia, USA
  • 12:00 Novel antivirals targeting influenza virus-specific membrane rafts Raft modulating aminosteroids as a new class of anti-influenza compounds
    Dr Cornelia Schroeder, Jado Technologies, Dresden, Germany
  • 12:10 T cell response to inactivated influenza vaccine in immunocompromised patients
    Dr Kathleen E. Sullivan, Chief, Division of Allergy and Immunology, Associate Professor of Pediatrics, The Children's Hospital of Philadelphia, USA
  • 12:20 Replication deficient intranasal DEL-NS1 H5N1 influenza vaccine
    Dr Julia Romanova, Green Hills Biotechnology AG, Vienna, Austria
  • 12:30 Control of avian influenza vaccine potency through oil adjuvant design
    Dr Laurent Dupuis, Marketing & Development manager, Vaccine & Injectable Business Unit SEPPIC, Paris La Defense, France
  • 12:40 Immunization with Low Dose Adjuvanted Split H5N1 Pandemic Vaccine Protects Ferrets Against Homologous and Heterologous Challenge
    Dr Benoit Baras, GlaxoSmithKline Biologicals, Rixensart, Belgium

12:50 - Discussion and remarks

13:00 - Lunch

Session 5 - Prevention of Avian influenza in animals

14:00 - Avian influenza: State of the art Implementation of vaccination: the do’s and don’ts
Dr Christianne Bruschke, OIE, World Organisation for Animal Health, Paris, France

14:20 Early detection and application of preventive measures
Dr Stefano Marangon, Instituto Zooprofilattico Sperimentale delle Venezie, Padova, Italy

14:40 - Predicting the global spread of H5N1 avian influenza
Dr Marm Kilpatrick, Consortium for Conservation Medicine, New-York, USA

15:00 - Short oral communications for sessions 4 and 5

  • 15 :00 EFSA scientific opinion on vaccination against avian influenza if H5 and H7 subtypes in domestic poultry and captive birds
    Dr Oriol Ribo, Animal Health and Animal Welfare (AHAW) Unit, European Food Safety Authority (EFSA), Parma, Italy
  • 15:10 Novel polymer vaccine protects ferrets against lethal challenge with highly pathogenic avian influenza virus
    Dr Andrew Cawthon, Battelle Biomedical Research Center, West Jefferson, Ohio, USA
  • 15 :20 Regional risk assessment for the introduction of avian influenza in poultry producing farms
    Ms Barbara Grabkowsky, Institute for Spatial analysis and Panning in areas of intensive Agriculture (ISPA), University of Vechta, Germany
  • 15:25 The spread and evolution of highly pathogenic avian influenza (HPAI) H5N1 in Western Africa
    Dr Mariette Ducatez, Institute of Immunology, National PublicHealth Laboratory, Luxembourg
  • 15:30 Monitoring of HPAI H5N1 viruses in Russia (2006-2007)
    Dr Elena Yudina, Federal State Research Institution State Research Center of Virology and Biotechnology “VECTOR”, Koltsovo, Russia
  • 15:35 Detection of low pathogenic avian influenza virs un wild birds in Catalonia (Spain)
    Dr Núria Busquets Martí, Investigadora, Campus de Bellaterra,edifici CReSA, Barcelona, Spain
  • 15:40 Avian Influenza tool management
    M. Richard Martinez, Project Manager Europe, Middle East & Africa DuPont Chemical Solutions La Défense, France
  • 15:45 Pathologic and immunomodulatory effects of a specific nutrient synergy against avian flu virus
    Dr Steve Harakeh, Animal Sciences Department, American University of Beirut, Lebanon
  • 15:50 Elicitation of protective immune responses to pandemic H5N1 Influenza following immunization with A/Indonesia/05/2005 Virus-like particle vaccines
    Dr Rick A. Bright, Novavax Inc., Rockville, USA
  • 15:55 A new high-yielding and robust production system for vaccine production
    Ms Nathalie Landry, Medicago Inc.,Quebec, Canada

16:00 - Discussion and conclusion

Disaster Management Response

The following questions will be discussed with the speakers and chairmen:
Pr van der Werf, Institut Pasteur, France
Pr Koos Van der Velden, EISS, The Netherlands
Dr Déirdre Hollingsworth, Imperial college of London, United Kingdom

  • Pandemic preparation: is Europe ready? Can the pandemic be predicted?
  • What are the practical measures and ethical outcomes of a pandemic outbreak?
  • Controlling of pandemic influenza spread: the example of travel restrictions
  • Avian Influenza eradication: why is it so difficult?

16:45 - End of the conference

© TASKFORCE INFECTIOUS DISEASE , all Rights Reserved, 2006